Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)
Keros Therapeutics (KROS) posted Enterprise Value of -$287.4 million for Q4 2025, up 58.56% on a QoQ basis from -$693.5 million in Q3 2025, and up 48.67% year-over-year from -$193.3 million in Q4 2024.
Keros Therapeutics (KROS) Enterprise Value (2019 - 2025) Analysis & Trends
Keros Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$287.4 million for Q4 2025.
- Quarterly Enterprise Value rose 48.67% year-over-year to -$287.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$287.4 million (up 48.67% YoY) and the FY2025 annual result came in at -$287.4 million, up 48.67% from the prior year.
- Enterprise Value was -$287.4 million for Q4 2025 at Keros Therapeutics, up from -$693.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$215.6 million in Q2 2022 and bottomed at -$720.5 million in Q1 2025.
- A 5-year average of -$376.5 million and a median of -$305.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 368.11% — and 2025, when it soared 48.67%.
- Keros Therapeutics' Enterprise Value stood at -$230.0 million in 2021, then retreated by 21.3% to -$279.0 million in 2022, then slipped by 18.67% to -$331.1 million in 2023, then tumbled by 69.09% to -$559.9 million in 2024, then surged by 48.67% to -$287.4 million in 2025.
- Business Quant data shows KROS's Enterprise Value at -$287.4 million in Q4 2025, -$693.5 million in Q3 2025, and -$690.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | -287.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -287.40 Mn |
| Sep 30, 2025 | -693.47 Mn |
| Jun 30, 2025 | -690.22 Mn |
| Mar 31, 2025 | -720.54 Mn |
| Dec 31, 2024 | -559.93 Mn |
| Sep 30, 2024 | -530.68 Mn |
| Jun 30, 2024 | -405.86 Mn |
| Mar 31, 2024 | -442.44 Mn |
| Dec 31, 2023 | -331.15 Mn |
| Sep 30, 2023 | -287.89 Mn |
| Jun 30, 2023 | -322.03 Mn |
| Mar 31, 2023 | -351.43 Mn |
| Dec 31, 2022 | -279.05 Mn |
| Sep 30, 2022 | -239.43 Mn |
| Jun 30, 2022 | -215.62 Mn |
| Mar 31, 2022 | -228.59 Mn |
| Dec 31, 2021 | -230.04 Mn |
| Sep 30, 2021 | -221.35 Mn |
| Jun 30, 2021 | -237.11 Mn |
| Mar 31, 2021 | -255.20 Mn |